KLP Kapitalforvaltning AS Buys 9,000 Shares of USANA Health Sciences, Inc. $USNA

KLP Kapitalforvaltning AS raised its stake in shares of USANA Health Sciences, Inc. (NYSE:USNA) by 82.6% during the 2nd quarter, according to its most recent filing with the SEC. The firm owned 19,900 shares of the company’s stock after acquiring an additional 9,000 shares during the period. KLP Kapitalforvaltning AS owned approximately 0.11% of USANA Health Sciences worth $608,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. PNC Financial Services Group Inc. lifted its stake in USANA Health Sciences by 339.6% during the 1st quarter. PNC Financial Services Group Inc. now owns 998 shares of the company’s stock valued at $27,000 after acquiring an additional 771 shares during the period. AlphaQuest LLC lifted its stake in shares of USANA Health Sciences by 300.9% in the 1st quarter. AlphaQuest LLC now owns 3,412 shares of the company’s stock worth $92,000 after purchasing an additional 2,561 shares during the period. US Bancorp DE lifted its stake in shares of USANA Health Sciences by 13.1% in the 1st quarter. US Bancorp DE now owns 4,611 shares of the company’s stock worth $124,000 after purchasing an additional 535 shares during the period. State of Wyoming lifted its stake in shares of USANA Health Sciences by 273.1% in the 1st quarter. State of Wyoming now owns 5,216 shares of the company’s stock worth $141,000 after purchasing an additional 3,818 shares during the period. Finally, GAMMA Investing LLC lifted its stake in shares of USANA Health Sciences by 49,082.4% in the 1st quarter. GAMMA Investing LLC now owns 8,361 shares of the company’s stock worth $225,000 after purchasing an additional 8,344 shares during the period. Institutional investors own 54.25% of the company’s stock.

Insider Buying and Selling

In related news, Director Gilbert A. Fuller sold 1,058 shares of the firm’s stock in a transaction on Thursday, August 7th. The shares were sold at an average price of $29.10, for a total value of $30,787.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider David Mulham Mulham sold 3,515 shares of the firm’s stock in a transaction on Wednesday, July 30th. The shares were sold at an average price of $30.26, for a total transaction of $106,363.90. Following the completion of the transaction, the insider directly owned 9,260 shares of the company’s stock, valued at approximately $280,207.60. This trade represents a 27.51% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.63% of the company’s stock.

USANA Health Sciences Price Performance

Shares of USNA opened at $20.89 on Friday. USANA Health Sciences, Inc. has a 1 year low of $19.88 and a 1 year high of $41.83. The company has a 50 day simple moving average of $28.82 and a two-hundred day simple moving average of $29.06. The firm has a market cap of $381.66 million, a P/E ratio of 11.61, a price-to-earnings-growth ratio of 1.03 and a beta of 0.61.

USANA Health Sciences (NYSE:USNA) last announced its quarterly earnings data on Thursday, October 9th. The company reported $0.56 earnings per share (EPS) for the quarter. USANA Health Sciences had a net margin of 3.79% and a return on equity of 9.48%. The business had revenue of $200.22 million during the quarter. USANA Health Sciences has set its Q3 2025 guidance at -0.150–0.150 EPS. On average, sell-side analysts anticipate that USANA Health Sciences, Inc. will post 2.45 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on USNA shares. Weiss Ratings reiterated a “sell (d+)” rating on shares of USANA Health Sciences in a research note on Wednesday, October 8th. Zacks Research cut shares of USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a research note on Monday, September 22nd. Finally, Wall Street Zen cut shares of USANA Health Sciences from a “buy” rating to a “hold” rating in a research note on Saturday, October 11th. Three analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Reduce” and a consensus target price of $36.00.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.